Physician profile
Thomas E Keane
NPI 1972558708
$52,211.89
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $12K · 2021: $15K · 2022: $1,260 · 2023: $952 · 2024: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $740 · Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $740.00 |
| Food and Beverage | $337.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13,464.75 | 2019-2020 | |
| Myovant Sciences INC. | $11,670.62 | 2021 | |
| Ferring International Center Sa | $4,975.00 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $4,530.60 | 2019 | |
| Janssen Scientific Affairs, LLC | $3,767.07 | 2019-2022 | |
| Clovis Oncology, INC. | $3,281.19 | 2019 | |
| Ferring Sendirian Berhad | $2,785.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,296.00 | 2020 | |
| Astellas Pharma US INC | $2,258.75 | 2021 | |
| Pfizer INC. | $1,297.51 | 2019-2024 | |
| Blue Earth Diagnostics | $1,200.81 | 2019-2022 | |
| Boston Scientific Corporation | $328.45 | 2019 | |
| Urogen Pharma, INC. | $141.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $131.94 | 2019 | |
| Astellas Pharma Global Development | $64.00 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $18.98 | 2023 | Urolift |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Keane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.